Skip to navigation menu Skip to content
Provider News

April New Resource Roundup

April 1, 2026

Updated Montana Outreach Flyer

If you care for patients who are seen in one of our Montana outreach sites, review our updated flyer for the most up-to-date information on deployment schedules, clinic providers and referral information.

Seattle Children’s Is Currently Enrolling Patients for the IMPACT Study

Researchers at Seattle Children’s are enrolling patients in the IMPACT study, a phase 1 clinical trial investigating the efficacy of a novel cancer treatment using glypican 3-targeting chimeric antigen receptor (GPC3-CAR) T-cells for solid tumor malignancies.

Current treatments for solid tumor malignancies include invasive options such as surgery and radiation therapy, which could pose serious complications in certain individuals.

In this study, researchers have genetically engineered autologous T-cells to express GPC3-CAR. This allows T-cells to recognize tumor cells expressing GPC3. To make GPC3-CAR T-cells more effective against tumor cells, two additional genes (IL15 and IL21) were added to improve CAR T-cell expansion and antitumor activity.

Researchers are planning to enroll participants from birth to 26 years of age who qualify for enrollment criteria. To refer a patient to this trial, contact [email protected].

New Infantile Spasms Clinical Standard Work Pathway

Infantile spasms is an epilepsy syndrome in which seizures (spasms) often occur alongside developmental changes and require urgent treatment. The new Infantile Spasms pathway standardizes the evaluation and diagnostic work-up for patients with suspected infantile spasms. It also includes treatment recommendations, parent education for new diagnoses, and outpatient follow-up guidelines with involvement from the primary care provider. For more information or questions, contact [email protected].

Recent Grand Rounds Recordings Available

Seattle Children's hosts grand rounds on a weekly basis. Here are some recent talks we think may be of interest: